Table 1.

IGABA stability of GABAA receptors microtransplanted to oocytes from MTLE neocortex, increased with a few exceptions by treatement with different AR antagonists

Drug treatment (dose)Tested oocytes (frogs) [patients]IGABA, %, before treatment (n)IGABA, %, after treatmentP
ANR82 (100 nM) [A2A antagonist]31 (4) [1, 3, and 4]92 ± 4 (3)82 ± 3<0.01
63.2 ± 2.5 (19)77.4 ± 2.2<0.001
ANR94 (100 nM) [A2A antagonist]22 (4) [2–5]51.3 ± 5.0 (3)38.7 ± 4.4<0.01
63.8 ± 3.3 (11)80.8 ± 4.4<0.001
ANR152 (100 nM) [A2A and A1 antagonist]22 (4) [2 and 3]77.9 ± 3.9 (11)98.8 ± 4.3<0.001
ANR235 (100 nM) [A3 antagonist]17 (4) [2, 3, and 5]71.4 ± 3.3 (13)88.6 ± 3.6<0.001
  • n, number of oocytes tested with AR antagonists. Sets of cells in which rundown increases and n values are in bold. IGABA (%) values represent the sixth IGABA amplitude normalized to the first of the rundown protocol. ANR152 at 100 nM also antagonizes A1; see Table S2.